Eisbach Bio GmbH

Eisbach Bio is a trailblazing biotechnology start-up that was established in 2019 as a spin-out of the Biomedical Center Munich. The company's primary focus is on targeting synthetic lethality in cancer through the development of groundbreaking drugs that effectively combat molecular vulnerabilities found in cancer genomes.

Having raised a remarkable $4.50M in its Seed Round investment on 21st March 2024, this German-based company has attracted the interest and support of the Cancer Focus Fund. With a bold slogan of "Eisbach will beat cancer at its own game," the company is driven to revolutionize the fight against cancer.